ArticleCancers2021
Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Molecularly Classified Endometrial Carcinoma.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- The Genetic Landscape of Colorectal Cancer: From Molecular Alterations to Therapeutic Decision Pathways.Cancers · 2026Review
- MMR deficient dedifferentiated endometrial carcinoma with synchronous uterine leiomyosarcoma: a rare collision tumour-case report and literature review.Oxford medical case reports · 2026Article
- MLH1 Promoter Variant -93G>A and Breast Cancer Susceptibility: Evidence from Azerbaijan.Biomedicines · 2025Article
- Article
- Expression of Programmed Death Ligand 1 [PD-L1] and Mismatch Repair Status in Squamous Cell Carcinomas of Cervix.Journal of obstetrics and gynaecology of India · 2024Article
- Clinicopathological Implications of Mismatch Repair Status in Endometrioid Endometrial Cancer in Duhok City.Cureus · 2024Article
- Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.Cancer · 2024Review
- Clinical analysis of molecular typing of 146 cases of endometrial carcinoma.Frontiers in oncology · 2024Article
- Review
- Comparison of Tissue Mismatch Repair Protein Deficiency between Early- and Advanced-Stage Endometrial Cancer.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Epigenetic MMR defect identifies a risk group not accounted for through traditional risk stratification algorithms in endometrial cancer.Frontiers in oncology · 2023Article
- Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas.Journal of mid-life healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The aggressiveness of mismatch repair (MMR) deficient endometrial carcinomas was examined in a single institution retrospective study. Outcomes were similar for MMR proficient (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.